Internal Medicine

A systematic review and meta-analysis of nearly 3 dozen published articles details the apparent increase in risk of cardiovascular disease and diabetes associated with a diagnosis of autism.

A new review shows a majority of COVID-19 randomized, controlled trial preprints have been published with changes to the components of the original findings.

The clinical trials that supported the FDA decision, SEQUOIA and ALPINE, evaluated the efficacy of zanubrutinib and findings paved the way to add the therapy as a treatment option.

The study population consists of patients who received 1-3 prior lines of therapy for relapsed and lenalidomide-refractory multiple myeloma.

The monoclonal antibody serves as the first and only therapy for treating hemolysis in adults with cold agglutinin disease, an extremely rare condition.

An analysis of 2 decades worth of data from the Clinical Practice Research Datalink suggests all-cause mortality rates in type 2 diabetes have decreased but sheds light on upward trends in mortality from multiple different forms of cancer, including pancreatic, liver, and lung cancer, particularly among older patients.

After addressing a 2021 CRL, Verrica Pharmaceuticals vies for the agent to become the first drug approved to treat the common skin infection.

A new study from clinicians in the VA Boston Healthcare System provides an overview of the impact the COVID-19 pandemic has had on racial disparities in wait times for new cardiology and orthopedic specialist consultations.

Clinician awareness is imperative with this comorbidity because overestimated asthma severity often results in over-treatment, according to investigators.

Using data from more than 500 patients with more than 6 years of follow-up suggests total caloric intake may be more effective for reducing weight loss than increasing the time between meals.

New data show patients who receive referred specialist care from a physician who went to medical school or other certification programs with their primary provider report better survey scores.

Qualitative interview analysis show male department chairs commonly witness discrimination against their female peers—yet they often are silent for a litany of reasons.

Promising results from the IMerge phase 3 clinical trial met the primary and secondary endpoints in the investigation of imetelstat, a novel telomerase inhibitor developed for hematologic malignancies.

Jesse Morse, MD, a sports medicine specialist, discusses commotio cordis and how to effectively communicate with athletes and parents of young athletes about the diagnosis in the wake of an incident where a player collapsed during a recent NFL game.

A group of investigators, researchers and policymakers discuss the issues, innovations and aspirations that may define 2023 advances.

From a topical gene therapy to a debated heart failure option, a litany of unique agents are anticipated for FDA decision in the new year.

The FDA's plans to expedite and expand regulatory pathways has resulted in a novel drug development boom since 2017. The commissioner discusses the details of their strategy.

Meta-analysis data show female, Black and Asian participants are generally underrepresented across studies assessing COVID-19 prevention or treatment strategies.

With a great deal of marginalized patients navigating burdensome, chronic, heterogenetic disease today, rheumatologists are becoming more invested in what the individual needs and wants from care.

New data revealed the amount of collective physician work hours in the US has been consistently declining for 20 years.

An analysis of a national health insurance database provides insight into the risk of total knee or total hip replacement based on use of metformin among a cohort of older adults.

The indication expands the marketed use of the atypical antipsychotic drug to be used with antidepressants in adult patients.

Using data from Medicare Advantage beneficiaries from 2011-2020, investigators provide an overview of trends of severe hyperglycemic- and hypoglycemic-related hospitalizations and emergency department visits among those with type 1 or type 2 diabetes.

With several newly approved therapies hitting the market and an overflowing pipeline, the FDA has stepped in to help keep the burgeoning world of biotech on track.

Previous studies aimed at understanding the association between intermittent hypoxia and impaired vigilance in patients with OSA provided conflicting results.

This year saw 4 new FDA approvals for the chronic condition. But dermatologists are still not satisfied.

New phase 2 interim data show rates of the erectile condition were halved after 26 weeks of treatment.

Beginning next year, the content, staff and experts from Practical Cardiology, Endocrinology Network and Rheumatology Network will be joining HCPLive.

"Acute myeloid leukemia (AML) remains the most deadly disease among adults, with a five year overall survival of less than 30%," lead investigator Dr. Molly Tokaz says in an interview.

According to data presented at the ASH 2022 Annual Meeting, this is the first suggestion of a hydroxyurea-related impact on mito activity in patients with sickle cell disease.